(Q33958519)

30 July 2017

1 reference

title

Emerging treatment options for patients with castration-resistant prostate cancer (English)

1 reference

30 July 2017

1 reference

ChEBI release 2020-05-28

1 reference

Daniel George

1

1 reference

PubMed ID

21748753

30 July 2017

Judd W Moul

series ordinal

2

1 reference

30 July 2017

11 July 2011

1 reference

30 July 2017

1 reference

30 July 2017

72

1 reference

30 July 2017

338-349

1 reference

30 July 2017

3

1 reference

Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer

30 July 2017

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21435

Progression of prostate cancer: multiple pathways to androgen independence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21435

Stroma-epithelium crosstalk in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21435

Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21435

Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21435

Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21435

Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21435

Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21435

Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21435

Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21435

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21435

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21435

Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21435

VEGF-Trap: a VEGF blocker with potent antitumor effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21435

Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21435

Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21435

Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21435

Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21435

The endothelin axis in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21435

Castration-resistant prostate cancer: from new pathophysiology to new treatment targets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21435

A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21435

Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21435

Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21435

Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21435

Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21435

Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21435

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21435

A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21435

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21435

A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21435

Denosumab in men receiving androgen-deprivation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21435

Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21435

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21435

Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21435

Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21435

21 January 2018

Identifiers

DOI

10.1002/PROS.21435

1 reference

30 July 2017

1 reference

PubMed ID

21748753